Zevra Therapeutics (ZVRA) Files Preliminary Proxy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Zevra Therapeutics Files Preliminary Proxy
March 31, 2025 4:12 PM EDTConfirms Receipt of Two Director Nominees from Daniel J. Mangless
Stockholders Are Not Required to Take Action at This Time
CELEBRATION, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (Nasdaq:GS ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies to people living with rare disease, today announced it has filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (SEC) in connection with the Companys 2025 Annual Meeting of Stockholders (Annual Meeting). Stockholders do not need to take any action with respect to the 2025 Annual... More
